No products in the cart.
Pre-made Zanidatamab benchmark antibody ( Bispecific mAb, anti-ERBB2/HER2;ERBB2/HER2 therapeutic antibody, Anti-CD340/HER-2/MLN 19/NEU/NGL/TKR1/VSCN2;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-639
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Zanidatamab biosimilar, Bispecific mAb, Anti-ERBB2/HER2;ERBB2/HER2 Antibody: Anti-CD340/HER-2/MLN 19/NEU/NGL/TKR1/VSCN2;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Zanidatamab is a bispecific antibody, based on Zymeworks’ Azymetric? platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding.
| Products Name (INN Index) | Pre-Made Zanidatamab biosimilar, Bispecific mAb, Anti-ERBB2/HER2;ERBB2/HER2 Antibody: Anti-CD340/HER-2/MLN 19/NEU/NGL/TKR1/VSCN2;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody |
|---|---|
| INN Name | Zanidatamab |
| Target | ERBB2,ERBB2 |
| Format | Bispecific/biparatopic |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa,Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None;6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED |
| 99% SI Structure | None;1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC |
| 95-98% SI Structure | 1s78:FE:DC/4llu:AB:CD/1l7i:HL/4llw:CD:AB/5vsh:CD:EF:AB:HL/4lly:AB:CD;5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Zymeworks |
| Conditions Approved | NA |
| Conditions Active | Gastric cancer,Oesophageal cancer,Breast cancer,Solid tumours |
| Conditions Discontinued | Ovarian cancer |
| Development Tech | Azymetric? platform(the mutation in CH3 to promote the heterogeneous of bispecific Abs, the mutations are: 1, T350V/L351Y/F405A/Y407V; 2, T350V/T366L/K392L/T394W) |
| Previous Name | NA |
| Gm Offical Target Name | ERBB2,ERBB2 |
| Package |
Previous slide
Next slide
